Peak Nasal Inspiratory Flow and Total Nasal Symptom Score for placebo nasal spray in an allergic rhinitis Environmental Exposure Chamber study

2005 ◽  
Vol 115 (2) ◽  
pp. S94
Author(s):  
H. Margalias ◽  
P. Patel ◽  
M. Hilmer ◽  
D. Dubins ◽  
M. Brubaker ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Score ◽  
Environmental Exposure ◽  
Nasal Spray ◽  
Nasal Symptom ◽  
Exposure Chamber ◽  
Total Nasal Symptom Score ◽  
Chamber Study ◽  
Environmental Exposure Chamber ◽  
Peak Nasal Inspiratory Flow

Onset of Action of Azelastine Nasal Spray Compared with Mometasone Nasal Spray and Placebo in Subjects with Seasonal Allergic Rhinitis Evaluated in an Environmental Exposure Chamber

2007 ◽  
Vol 21 (4) ◽  
pp. 499-503 ◽  
Author(s):  
Piyush Patel ◽  
Carrie D'Andrea ◽  
Harry J. Sacks
Keyword(s):  
Allergic Rhinitis ◽  
Environmental Exposure ◽  
Nasal Spray ◽  
Seasonal Allergic Rhinitis ◽  
Allergen Challenge ◽  
Nasal Symptom ◽  
Exposure Chamber ◽  
Onset Of Action ◽  
Environmental Exposure Chamber ◽  
Time Point

Background The objective of this study was to determine the onset of action of azelastine hydrochloride nasal spray compared with placebo and an intranasal steroid, mometasone furoate, in subjects with seasonal allergic rhinitis (SAR). Methods Subjects with a history of SAR and symptomatic while exposed to ragweed pollen in an environmental exposure chamber (EEC) were randomized to azelastine nasal spray (n = 150), mometasone nasal spray (n = 150), or placebo (n = 150) and recorded total nasal symptom scores (TNSS), consisting of sneezing, nasal pruritus, rhinorrhea, and congestion, during an 8-hour study period. Results Azelastine nasal spray showed a statistically significant improvement in the TNSS at 15 minutes compared with placebo. The effect was durable at each time point during the 8-hour study. Azelastine nasal spray also was significantly more effective than mometasone at each time point. Conclusion Azelastine nasal spray has a rapid (15 minute) onset of action. Azelastine nasal spray was superior to both placebo and mometasone nasal spray in reducing nasal symptoms of SAR occurring within 8 hours after an allergen challenge.

scholarly journals Therapeutic comparability of Dezrinit and Nazonex® in control of symptoms of allergic rhinitis. The results of a multicenter, open, randomized, comparative study in parallel groups

2016 ◽  
Vol 13 (3) ◽  
pp. 65-74
Author(s):  
N I Ilina ◽  
T G Fedoskova ◽  
N G Astafieva ◽  
L A Gorychkina ◽  
A S Edin ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Score ◽  
Nasal Spray ◽  
Nasal Symptom ◽  
Ocular Symptom ◽  
Mometasone Furoate ◽  
Total Nasal Symptom Score ◽  
Metered Dose ◽  
Comparison Groups ◽  
Receive Treatment

Background. To study efficacy and safety of Dezrinit (mometasone furoate, metered dose nasal spray, 200 pg/day) in comparison with Nasonex® (mometasone furoate, metered dose nasal spray, 200 pg/day) upon administration for 14 days in adult patients with seasonal allergic rhinitis. Materials and methods. A total of 141 patients were enrolled into the study at 8 study centers in the RF, of which 134 patients were randomized: 67 patients into the experimental group (Dezrinit) and 67 patients into the comparison group (Nasonex®). patients were randomized to receive treatment either with Dezrinit or Nasonex®. Efficacy was assessed based on reflective Total Nasal Symptom Score (rTNSS) and instantaneous Total Nasal Symptom Score (iTNSS); reflective Total Ocular Symptom Score (rTOSS) and instantaneous Total Ocular Symptom Score (iTOSS). Overall proportion of patients who responded to treatment was evaluated according to overall assessment of treatment efficacy both by a patient and by an investigator. AEs were reported for safety assessment. Results. After 14 days of treatment a marked improvement of symptoms was observed in both groups based on all assessed scores. Mean change (SD) in rTNSS from baseline was -11,91 (4,625) scores and -11,64 (4,58) scores in the experimental and comparison groups, respectively (within group differences, p

Sign in / Sign up

Export Citation Format

Share Document